- Pandemic had a push-pull effect in the final quarter, reducing sales of some goods while boosting hospital-surface disinfectant goods
- The group remains debt-free and has lifted the dividend by 12 per cent
IC TIP:
Buy
at
515p
As presaged in a summer-time update, Tristel’s (TSTL) full-year performance reflected the push-and-pull effects of the Covid-19 pandemic. On the one hand, the crisis dealt a £0.5m blow to the group’s medical-device decontamination sales – its main product portfolio. But on the other hand, revenues from its hospital surface disinfectant goods ticked up by £2m. Overall, during the March-to-June quarter – when the virus was at its peak in many regions – Tristel’s sales climbed by almost a third year-on-year to £11.8m.